| Literature DB >> 34155246 |
Rebecca Pedersini1,2, Pierluigi di Mauro3, Sara Bosio4, Barbara Zanini5, Alessandra Zanini3, Vito Amoroso3, Antonella Turla3, Lucia Vassalli3,4, Mara Ardine3, Sara Monteverdi3, Manuel Zamparini3, Cristina Gurizzan3, Deborah Cosentini3, Chiara Ricci5,6, Edda Lucia Simoncini4, Alfredo Berruti3.
Abstract
Change in eating habits in early breast cancer (EBC) patients during chemotherapy has been poorly studied in the literature. The primary aim of this study was to prospectively evaluate food preferences and weight change in EBC patients before and after adjuvant chemotherapy. From April 2014 to June 2018, 205 EBC patients underwent a dietary assessment according to the following timeline: baseline evaluation (one week before starting chemotherapy, T0); first follow-up (approximately 2-3 months after starting chemotherapy, T1); final follow-up (one week after chemotherapy end, T2). A statistically significant reduction of the following foods was reported after the start of chemotherapy: pasta or rice, bread, breadsticks/crackers, red meat, fat and lean salami, fresh and aged cheese, milk, yogurt, added sugar, soft drinks, alcoholic beverages (wine, beer, and schnapps), and condiments (oil and butter). Conversely, fruit consumption consistently increased. As a result of these changes, a Healthy Eating Index (HEI) specifically developed for this study and suggestive of a balanced diet, significantly increased. Body weight did not increase, despite reduction in physical activity. This prospective study shows that EBC patients tend to adopt "healthier dietary patterns" during adjuvant chemotherapy, leading to a non-change in weight, despite reduction in physical activity.Entities:
Year: 2021 PMID: 34155246 PMCID: PMC8217237 DOI: 10.1038/s41598-021-92138-7
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Clinical characteristics of the patients at baseline.
| Characteristic | Number of patients (%) (n = 205) |
|---|---|
| Median age (range) | 54 (25–80) |
| Premenopausal | 82 (40%) |
| Postmenopausal | 123 (60%) |
| 1 | 103 (50.2%) |
| ≥ 2 | 102 (49.8%) |
| 0 | 114 (55.6%) |
| ≥ 1 | 91 (44.4%) |
| No Special Type (NST) | 187 (91.3%) |
| Others | 18 (8.7%) |
| Positive | 140 (68.3%) |
| Negative | 65 (31.7%) |
| Positive | 115 (56%) |
| Negative | 90 (44%) |
| G1 or G2 | 20 (9.7%) |
| G3 | 168 (82%) |
| Unknown | 17 (8.3%) |
| < 20% | 30 (14.6%) |
| ≥ 20% | 169 (82.4%) |
| Unknown | 6 (3%) |
| Positive | 78 (38%) |
| Negative | 127 (62%) |
| Anthracyclines + taxanes (± trastuzumab) | 127 (62%) |
| Anthracyclines | 40 (19.6%) |
| Taxanes (± trastuzumab) | 19 (9.2%) |
| Others | 19 (9.2%) |
pT: pathological tumor stage; pN: pathological nodal stage; G1: well differentiated tumor; G2 moderately differentiated tumor; G3: undifferentiated tumor; HER2: Human epidermal growth factor receptor 2.
Food, beverages, and condiments consumption before, during and after chemotherapy.
| Food or beverage | Baseline (T0) | First follow-up (T1) | Final follow-up (T2) | |
|---|---|---|---|---|
| Fruit | 1829 (1662–1996) | 2165 (1992.7–2337.5) | 2249.3 (2077.8–2420.7) | < 0.001 |
| Vegetables | 1602.8 (1499.6–1706) | 1652.7 (1557.4–1747.9) | 1608.6 (1511.9–1705.3) | 0.249 |
| Pasta or rice | 390.3 (361–418.9) | 366 (340.3–391.6) | 362.7 (336–389) | 0.009 |
| Bread | 423.2 (380.5–465.8) | 323 (289.2–356.8) | 317.9 (285.3–350.5) | < 0.001 |
| Potatoes | 260 (230.4–289.6) | 255.6.6 (223.2–287.9) | 240.5 (212.2–268.7) | 0.392 |
| Breadsticks or crackers | 104.8 (85.3–124.4) | 78.8 (62.7–94.8) | 50.7 (38.3–63) | < 0.001 |
| White meat | 236.7 (214.5–258.8) | 225 (205–245) | 227 (207.4–246) | 0.487 |
| Red meat | 132 (117–148) | 102.7 (89.6–115.8) | 101.5 (89.7–113.3) | < 0.001 |
| Fish | 252 (228–276) | 262.6 (236–288.8) | 265.2 (239.8–290.6) | 0.956 |
| Lean salami | 92.8 (80.6–105) | 79 (67–91) | 61.7 (52.8–70.6) | < 0.001 |
| Fat salami | 28 (22–34) | 20.3 (14.8–25.9) | 14.4 (9.8–19) | < 0.001 |
| Eggs | 118.3 (103.8–1132.8) | 109.4 (96.2–122.6) | 108.3 (97.1–119.5) | 0.153 |
| Fresh cheese | 195 (169.5–220.5) | 165.2 (145.4–185) | 158.2 (137.8–178.5) | 0.039 |
| Aged cheese | 114.3 (97.9–130.8) | 95.6 (82.8–108.4) | 87.4 (74.8–100) | 0.011 |
| Legumes | 199.8 (171.7–228) | 214.8 (185.8–243.9) | 196.3 (168–224.5) | 0.592 |
| Milk | 448.3 (358–538.5) | 362.8 (283.6–441.9) | 376.9 (300–453) | 0.030 |
| Yogurt | 311.3 (237–385.5) | 244.5 (194.2–294.8) | 225.3 (176–274.5) | 0.022 |
| Sugar | 75.4 (62.9–87.8) | 57.7 (46.5–69) | 55.6 (45.4–65.8) | < 0.001 |
| Ice-creams | 78.4 (60.5–96.3) | 78.3 (61.5–95.7) | 70.4 (53.7–87) | 0.105 |
| Snacks | 170.2 (136–204.4) | 131.3 (103.4–159) | 143.5 (114.4–172.7) | 0.133 |
| Soft drinks | 225.7 (153.9–297.4) | 180 (123.2–236.8) | 138.8 (92.5–185) | 0.003 |
| Wine | 281.4 (218–344.7) | 166 (112.8–219.2) | 139.6 (100.3–178.9) | < 0.001 |
| Beer | 128.4 (84.2–172.5) | 66.4 (35.5–97.3) | 62.7 (35–90.5) | < 0.001 |
| Schnapps | 2.93 (0.81–5) | 1.12 (0.39–2.63) | 0.83 (0.53–2.8) | < 0.001 |
| Oil | 246 (233.6–258.4) | 235 (225.8–246) | 231 (221–241.8) | 0.029 |
| Butter | 18.6 (14.4–22.8) | 15.7 (11.9–19.4) | 14.4 (10.7–18.2) | 0.014 |
All measures are expressed as mean of grams per week or milliliters per week with corresponding 95% CI in brackets.
*Friedman’s test.
Calories intake, macronutrients, and HEI before and after chemotherapy.
| Daily dietary intake | Mean (IC 95%) at baseline (T0) | Mean (IC 95%) at final follow-up (T2) | |
|---|---|---|---|
| Total energy (kcal) | 1733.39 (1666.38–1800.39) | 1544.92 (1499.79–1590.04) | < 0.001 |
| Proteins (g) | 61.78 (59.38–64.18) | 54.825 (63.02–56.61) | < 0.001 |
| Proteins (kcal) | 247.14 (237.55–256.74) | 219.28 (121.11–226.45) | < 0.001 |
| Energy percentage (%) | 14.51 (14.17–14.85) | 14.28 (13.98–14.57) | 0.161 |
| Carbohydrates (g) | 180.96 (171.89–180.03) | 155.96 (149.72–162.20) | < 0.001 |
| Carbohydrates (kcal) | 723.85 (687.56–760.13) | 623.86 (598.91–648.80) | < 0.001 |
| Energy percentage (%) | 41.29 (00.40–0.42) | 40.02 (00.39–0.40) | 0.011 |
| Fat (g) | 79.96 (76.20–83.71) | 69.26 (66.99–71.53) | < 0.001 |
| Fat (kcal) | 719.67 (685.88–753.46) | 623.42 (602.99–643.86) | < 0.001 |
| Energy percentage (%) | 41.49 (40.36–42.61) | 40.58 (39.70–41.44) | 0.08 |
| HEI (score 0–24) | 15,4 (15–15.79) | 16,03 (15.66–16.40) | < 0.001 |
kcal kilocalories, g grams, HEI healthy eating index.
*Wilcoxon test.
Weight, BMI, and lifestyle variations.
| Baseline (T0) | First follow-up (T1) | Final follow-up (T2) | |||
|---|---|---|---|---|---|
Weight kg (95% CI) | 64.8 (63.1–66.5) | 64.8 (63.1–66.5) | 65.2 (63.5–66.9) | 0.202 | |
BMI kg/m2 (95% CI) | 24.7 (24.1–25.4) | 24.7 (24.1–25.4) | 24.9 (24.3–25.5) | 0.261 | |
Employment Number of patients | Yes | 152 (74.1%) | 87 (42.4%) | 89 (43.4%) | < 0.0001 |
| No | 53 (25.9%) | 118 (57.6%) | 116 (56.6%) | ||
Physical activity Number of patients | Yes | 108 (52.7%) | 90 (43.9%) | 89 (43.4%) | 0.036 |
| No | 97 (47.3%) | 115 (56.1%) | 116 (56.6%) | ||
kg kilograms, BMI body mass index.
*Friedman’s and Chi-squared test.
Change of food habits and HEI score across the three weight categories.
| Food or beverage | Decreased weight | Stable weight | Increased weight | |
|---|---|---|---|---|
| Baseline | 2211.11 (1716.81–2669.37) | 1737.50 (1544.80–1927.54) | 1914.71 (1513.29–2298.42) | 0.276 |
| Final follow-up | 2072.22 (1769.59–2372.01) | 2305.73 (2083.88–2511.98) | 2150.74 (1782.80–2501.19) | 0.790 |
| 0.754 | < 0.001 | 0.222 | ||
| Baseline | 1379.26 (1144.69–1613.83) | 1609.51 (1485.31–1733.71) | 1752.06 (1467.32–2036.79) | 0.202 |
| Final follow-up | 1540 (1306.92–1773.08) | 1584.72 (1469.24–1700.20) | 1764.541 (1490.93–2037.90) | 0.453 |
| 0.755 | 0.939 | 0.236 | ||
| Baseline | 487.96 (348.15–635.99) | 418.23 (370.49–467.01) | 392.65 (306.66–486.01) | 0.661 |
| Final follow-up | 317.59 (229.65–407.41) | 316.67 (277.27–357.28) | 323.53 (253.68–395.57) | 0.977 |
| 0.025 | < 0.001 | 0.073 | ||
| Baseline | 60.00 (28.89–101.10) | 108.33 (83.34–133.23) | 125.74 (82.07–172.06) | 0.072 |
| Final follow-up | 21.11 (8.33–36.67) | 56.04 (41.04–73.42) | 51.62 (29.12–76.32) | 0.263 |
| 0.04 | < 0.001 | < 0.004 | ||
| Baseline | 351.85 (250.03–453.67) | 244.79 (210.21–279.38) | 251.47 (187.55–315.39) | 0.088 |
| Final follow-up | 281.48 (218.42–344.54) | 229.51 (196.87–262.16) | 254.41 (163.17–345.66) | 0.232 |
| 0.529 | 0.852 | 0.209 | ||
| Baseline | 263.89 (191.61–336.16) | 238.19 (210.88–265.51) | 208.82 (168.54–249.11) | 0.686 |
| Final follow-up | 225 (186.31–263.69) | 232.64 (207.88–257.40) | 203.68 (158.78–248.57) | 0.654 |
| 0.812 | 0.797 | 0.254 | ||
| Baseline | 146.30 (117.59–185.19) | 128.12 (110.43–147.39) | 140.44 (102.21–180.84) | 0.255 |
| Final follow-up | 113.89 (82.41–152.78) | 102.95 (88.20–118.05) | 85.29 (65.44–105.15) | 0.672 |
| 0.179 | 0.012 | 0.04 | ||
| Baseline | 272.22 (211.80–332.65) | 232.99 (207.50–258.47) | 316.91 (231.78–402.05) | 0.123 |
| Final follow-up | 269.44 (209.96–328.93) | 250.35 (223.11–277.59 | 325 (232.94–417.06) | 0.360 |
| 0.187 | 0.851 | 0.893 | ||
| Baseline | 98.89 (68.15–135.90) | 90.66 (77.26–105.52) | 97.50 (70.60–127.05) | 0.508 |
| Final follow-up | 67.59 (50.00–86.09) | 59.20 (49.58–69.06) | 67.79 (45.44–96.17) | 0.417 |
| 0.274 | < 0.001 | 0.055 | ||
| Baseline | 20.37 (10.00–34.26) | 26.11 (20.56–32.25) | 42.65 (20.89–69.11) | 0.477 |
| Final follow-up | 12.04 (4.63–21.30) | 12.22 (8.13–16.63) | 25.74 (10.29–47.65) | 0.333 |
| 0.148 | < 0.001 | 0.067 | ||
| Baseline | 218.52 (153.73–288.89) | 197.22 (167.54–226.74) | 166.91 (116.91–236.01) | 0.485 |
| Final follow-up | 182.41 (128.70–236.11) | 159.55 (135.07–185.07) | 133.09 (97.81–170.59) | 0.451 |
| 0.206 | 0.035 | 0.455 | ||
| Baseline | 86.11 (56.30–120.36) | 113.96 (93.80–134.58) | 138.38 (105.59–176.02) | 0.073 |
| Final follow-up | 80.37 (49.64–112.22) | 87.74 (72.81–103.02) | 91.91 (62.06–121.76) | 0.966 |
| 0.986 | 0.029 | 0.068 | ||
| Baseline | 88.89 (57.94–119.84) | 123.78 (105.28–142.29) | 118.38 (86.95–149.82) | 0.146 |
| Final follow-up | 86.11 (58.91–113.31) | 111.63 (97.31–125.95) | 111.76 (89.53–134) | 0.266 |
| 0.185 | 0.875 | 0.917 | ||
| Baseline | 197.22 (124.12–270.33) | 206.94 (171.04–242.85) | 172.06 (117.79–226.33) | 0.835 |
| Final follow-up | 149.07 (93.03–205.12) | 200.69 (165.32–236.07) | 215.44 (145.13–285.75) | 0.538 |
| 0.378 | 0.759 | 0.348 | ||
| Baseline | 577.78 (302.42–853.14) | 469.10 (354.86–583.34) | 257.35 (129.79–384.91) | 0.178 |
| Final follow-up | 511.11 (289.29–732.94) | 372.40 (277.48–467.31) | 289.71 (143.21–436.21) | 0.630 |
| 0.487 | 0.083 | 0.618 | ||
| Baseline | 368.06 (118.06–833.22) | 334.64 (255.23–414.90) | 167.28 (97.43–250.00) | 0.323 |
| Final follow-up | 145.83 (76.39–229.17) | 246.96 (189.67–309.46) | 196.69 (91.91–343.66) | 0.927 |
| 0.382 | 0.019 | 0.745 | ||
| Baseline | 60.28 (33.70–86.85) | 86.28 (70.40–103.61) | 41.40 (23.68–60.36) | 0.011 |
| Final follow-up | 36.85 (15.57–59.61) | 60.40 (48.54–74.11) | 50.51 (28.82–75.22) | 0.109 |
| 0.015 | < 0.001 | 0.398 | ||
| Baseline | 116.41 (70.18–162.64) | 128.41 (106.58–150.23) | 171.50 (113.17–229.83) | 0.361 |
| Final follow-up | 107.72 (66.56–148.89) | 104.81 (86.18–123.43) | 134.13 (85.27–183) | 0.586 |
| 0.917 | 0.077 | 0.117 | ||
| Baseline | 118.89 (46.74–191.04) | 181.04 (136.15–225.93) | 165 (104.33–225.67) | 0.178 |
| Final follow-up | 157.78 (78.74–236.81) | 142.50 (106.01–178.99) | 136.76 (73.79–199.74) | 0.630 |
| 0.159 | 0.181 | 0.555 | ||
| Baseline | 180.56 (56.74–356.33) | 298.18 (226.15–380.62) | 290.44 (171.90–431.87) | 0.136 |
| Final follow-up | 119.21 (32.41–234.84) | 144.10 (102.00–200.28) | 136.95 (63.44–229.76) | 0.330 |
| 0.187 | < 0.001 | 0.004 | ||
| Baseline | 125.28 (12.22–323.89) | 130.05 (79.64–186.76) | 123.75 (58.24–211.04) | 0.278 |
| Final follow-up | 9.17 (0.00–27.50) | 71.04 (38.96–112.86) | 70.37 (26.69–121.32) | 0.095 |
| 0.141 | 0.001 | 0.066 | ||
| Baseline | 1.48 (0.00–4.07) | 3.33 (0.77–6.73) | 2.35 (0.29–5.29) | 0.736 |
| Final follow-up | 0.37 (0.00–1.11) | 1.11 (0.00–3.19) | 0.00 (0.00–0.00) | 0.574 |
| 0.18 | 0.008 | 0.063 | ||
| Baseline | 233.33 (199.63–264.44) | 245.24 (231.40–259.58) | 259.41 (224.41–294.41) | 0.575 |
| Final follow-up | 271.11 (242.99–295.56) | 225.28 (212.43–238.44) | 226.47 (202.07–251.46) | 0.022 |
| 0.066 | 0.014 | 0.038 | ||
| Baseline | 12.04 (5.61–18.46) | 19.44 (13.92–24.97) | 20.44 (12.23–28.65) | 0.373 |
| Final follow-up | 11.85 (6.47–17.23) | 14.58 (9.79–19.38) | 15.88 (6.42–25.35) | 0.608 |
| 0.981 | 0.077 | 0.071 | ||
| Baseline | 15.11 (14.06–16.16) | 15.59 (15.15–16.03) | 14.91 (13.86–15.96) | 0.394 |
| Final follow-up | 15.74 (14.69–16.80) | 16.20 (15.77–16.63) | 15.53 (14.48–16.58) | 0.475 |
| 0.481 | 0.018 | 0.208 | ||
All measures are expressed as mean of grams per week or milliliters per week with corresponding 95% CI in brackets. HEI: Healthy Eating Index.
*Kruskal–Wallis test in rows; Wilcoxon test in columns.